Antibodies against tumor necrosis factor are a highly effective treatment for Crohn's disease, as measured by disease-activity indices. But what influence does this type of therapy have on the health-related quality of life of patients with Crohn's disease?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cohen, R. D. The quality of life in patients with Crohn's disease. Aliment. Pharmacol. Ther. 9, 1603–1609 (2002).
Sandborn, W. J. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135, 1442–1447 (2008).
Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52–65 (2007).
Loftus, E. V. et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am. J. Gastroenterol. 103, 3132–3141 (2008).
Feagan, B. G. Review article: economic issues in Crohn's disease—assessing the effects of new treatments on health-related quality of life. Aliment. Pharmacol. Ther. 13 (Suppl. 4), 29–37 (1999).
Verissimo, R. Quality of life in inflammatory bowel disease: psychometric evaluation of an IBDQ cross-culturally adapted version. J. Gastrointest. Liver Dis. 17, 439–444 (2008).
Feagan, B. G., Yan, S., Bala, M., Bao, W. & Lichtenstein, G. R. The effects of infliximab maintenance therapy on health-related quality of life. Am. J. Gastroenterol. 98, 2232–2238 (2003).
Rutgeerts, P. et al.; CDP870 Crohn's Disease Study Group. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int. J. Colorectal Dis. 23, 289–296 (2008).
Podolsky, D. K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417–429 (2002).
Feagan, B. G. et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135, 1493–1499 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Papadakis, K. Adalimumab improves quality of life. Nat Rev Gastroenterol Hepatol 6, 200–201 (2009). https://doi.org/10.1038/nrgastro.2009.39
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2009.39
